Clinical Trials Browser

Phase 2 × Pancreatic Neoplasms × olaparib × Clear all

NCT04548752 2026-03-18

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04753879 2025-12-04

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06078787 2024-05-06

PALBOLA

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02511223 2023-04-19

10

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms